Syndax Pharmaceuticals (SNDX) investor relations material

Business highlights and product launches

• Two commercial products launched: Revuforj (for AML/ALL) and Niktimvo (for chronic GVHD), both showing strong uptake and performance in their first year.

• Revuforj expanded its label to include NPM1, now covering 40-50% of AML/ALL patients, with significant off-label use and positive physician feedback.

• Niktimvo is dominating the fourth-line GVHD setting and expanding into third-line, with high patient persistency and robust commercial growth.

• Both products are supported by a unified field force and target overlapping physician audiences, optimizing commercial execution.

• The company sees a $2 billion opportunity in relapsed/refractory settings, with potential to expand further as indications grow.

Clinical data and physician feedback

• Revuforj demonstrates a 50% overall response rate, with rapid tumor clearance and extended remission, especially valued in an efficacy-driven market.

• Duration of response for NPM1 patients reaches up to 23 months, and the drug is well tolerated with flexible dosing options.

• Physicians report no change in prescribing behavior after the addition of a QT monitoring requirement, as such monitoring is routine.

• About one-third of KMT2A patients receive a transplant, with 35-40% returning for maintenance therapy; these numbers are expected to rise.

• Niktimvo shows long-term patient retention, with some on therapy for up to three years, and strong support for its efficacy and tolerability.

Pipeline, studies, and future opportunities

• Revuforj is being studied in frontline AML/ALL settings, with pivotal Evolve and Reveal trials underway, aiming for accelerated and full approvals.

• Early data in frontline combinations (Venaza and 7+3) show high response and MRD rates, with further updates expected at ASH.

• Niktimvo is being advanced in earlier GVHD lines and in combination with steroids and Jakafi, with data expected in 2026-2027.

• A phase 2 trial for Niktimvo in IPF is enrolling well, with data anticipated in the second half of next year and a large market opportunity identified.

• Over 20 ASH presentations are planned, including real-world evidence and pivotal study follow-ups for both products.